

Retraction: MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1

Yang Lin¹, Tianmin Xu¹, Shunqing Zhou¹ and Manhua Cui¹

¹Department of Obstetrics and Gynecology, The Second Hospital, Jilin University, Nangan District, Changchun 130041, China

Published: June 12, 2023

Copyright: © 2023 Lin et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: A number of figure images in this paper were previously published in earlier papers. Figure 2E contains images from Figure 6C of another paper [1]. Figure 5D also contains images from two other published papers which have since been retracted [2, 3]. Figure 2C also contains images from Figure 2C of another published paper [4]. Images in Figure 3B and 5F are sourced from another published paper [5]. Figure 6B also contains images from another published paper [6]. Figure 5B has an image from Figure 4D in another published paper [7]. In addition, the authors are unable to reproduce the results represented in the paper. As a result, all authors have agreed to this retraction.

REFERENCES

1. Lin Y, Cheng K, Wang T, Xie Q, Chen M, Chen Q, Wen Q. miR-217 inhibits proliferation, migration, and invasion via targeting AKT3 in thyroid cancer. *Biomed Pharmacother.* 2017; 95:1718–24. <https://doi.org/10.1016/j.biopha.2017.09.074>. [PubMed]
2. Li R, Dong B, Wang Z, Jiang T, Chen G. MicroRNA-361-5p inhibits papillary thyroid carcinoma progression by targeting ROCK1. *Biomed Pharmacother.* 2018; 102:988–95. <https://doi.org/10.1016/j.biopha.2018.03.122>. [PubMed]. Retraction in: *Biomed Pharmacother.* 2023; 114723. <https://doi.org/10.1016/j.biopha.2023.114723>. [PubMed]
3. Niu JT, Zhang LJ, Huang YW, Li C, Jiang N, Niu YJ. MiR-154 inhibits the growth of laryngeal squamous cell carcinoma by targeting GALNT7. *Biochem Cell Biol.* 2018; 96:752–60. <https://doi.org/10.1139/bcb-2018-0047>. [PubMed]. Retraction in: *Biochem Cell Biol.* 2023; 101:197. <https://doi.org/10.1139/bcb-2023-0037>. [PubMed]
4. Fei D, Sui G, Lu Y, Tan L, Dongxu Z, Zhang K. The long non-coding RNA-ROR promotes osteosarcoma progression by targeting miR-206. *J Cell Mol Med.* 2019; 23:1865–72. <https://doi.org/10.1111/jcmm.14087>. [PubMed]
5. Yu B, Lv X, Su L, Li J, Yu Y, Gu Q, Yan M, Zhu Z, Liu B. MiR-148a Functions as a Tumor Suppressor by Targeting CCK-BR via Inactivating STAT3 and Akt in Human Gastric Cancer. *PLoS One.* 2016; 11:e0158961. <https://doi.org/10.1371/journal.pone.0158961>. [PubMed]
6. Teng Y, Zhang Y, Qu K, Yang X, Fu J, Chen W, Li X. MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3. *Oncotarget.* 2015; 6:40799–814. <https://doi.org/10.18632/oncotarget.5695>. [PubMed]
7. Kim HS, Lee KS, Bae HJ, Eun JW, Shen Q, Park SJ, Shin WC, Yang HD, Park M, Park WS, Kang YK, Nam SW. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. *Oncotarget.* 2015; 6:8089–102. <https://doi.org/10.18632/oncotarget.3512>. [PubMed]

Original article: *Oncotarget.* 2017; 8:101649–101658. <https://doi.org/10.18632/oncotarget.21417>